Our proposed model for the oncogenicity of MYB fusions in BPDCN is that they directly induce aberrant binding to G2/M cell cycle promoters via B-MYB binding sites, which results in deregulated expression of these genes and overriding of the G2/M checkpoint. Here, MYB is linked to CD4+/CD56+ hematodermic neoplasm.